臨床眼科78巻11号

2024年10月発行

増刊号 6年前の常識は現在の非常識！—AI時代へ向かう今日の眼科医へ

Ⅷ．網膜

抗VEGF薬の新しい展開

著者： 安川力¹

所属機関： ¹名古屋市立大学大学院医学研究科視覚科学

ページ範囲：P.210 - P.215

文献概要

ここが変わった！

以前の常識

・薬剤①：ラニビズマブとアフリベルセプトのみ

・薬剤②：先行バイオ医薬品のみ

・投与レジメン：必要に応じて（PRN），2か月に1回（bimonthly），treat and extend（TAE）

・適応：新生血管型加齢黄斑変性，近視性脈絡膜新生血管，糖尿病黄斑浮腫，網膜静脈閉塞症に伴う黄斑浮腫

現在の常識

・薬剤①：ブロルシズマブ，ファリシマブが登場

・薬剤②：バイオシミラーが登場

・投与レジメン：レスキュー付き3〜4か月ごと投与

・適応：血管新生緑内障，未熟児網膜症

参考文献

1）Dugel PU, Koh A, Ogura Y, et al：HAWK and HARRIER：phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127：72-84, 2020

2）Dugel PU, Singh RP, Koh A, et al：HAWK and HARRIER：ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128：89-99, 2021

3）Brown DM, Emanuelli A, Bandello F, et al：KESTREL and KITE：52-week results from two phase Ⅲ pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol 238：157-172, 2022

4）Monés J, Srivastava SK, Jaffe GJ, et al：Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab：post hoc review of HAWK and HARRIER. Ophthalmology 128：1050-1059, 2021

5）Maruko I, Okada AA, Iida T, et al：Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration：a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol 259：2857-2859, 2021

6）Hikichi T：Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation. Graefes Arch Clin Exp Ophthalmol 260：2529-2535, 2022

7）Joussen AM, Ricci F, Paris LP, et al：Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases：a review of preclinical data. Eye（Lond） 35：1305-1316, 2021

8）Heier JS, Khanani AM, Ruiz CQ, et al：Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration（TENAYA and LUCERNE）：two randomized, double-masked, phase 3, non-inferiority trials. Lancet 399：729-740, 2022

9）Khanani AM, Kotecha A, Chang A, et al：TENAYA and LUCERNE：two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology 131：914-926, 2024

10）Wykoff CC, Abreu F, Adamis AP, et al：Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema（YOSEMITE and RHINE）：two randomized, double-masked, phase 3 trials. Lancet 399：741-755, 2022

11）Wong TY, Haskova Z, Asik K, et al：Faricimab treat-and-extend for diabetic macular edema：two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology 131：708-723, 2024

12）Tadayoni R, Paris LP, Danzig CJ, et al：Efficacy and safety of faricimab for macular edema due to retinal vein occlusion：24-week results from the BALATON and COMINO trials. Ophthalmology 131：950-960, 2024

13）Lanzetta P, Korobelnik JF, Heier JS, et al：Intravitreal aflibercept 8mg in neovascular age-related macular degeneration（PULSAR）：48-week results from a randomized, double-masked, non-inferiority, phase 3 trial. Lancet 403：1141-1152, 2024

14）Brown DM, Boyer DS, Do DV, et al：Intravitreal aflibercept 8mg in diabetic macular oedema（PHOTON）：48-week results from a randomized, double-masked, non-inferiority, phase 2/3 trial. Lancet 403：1153-1163, 2024

15）Brwon DM, Wykoff CC, Wong TP, et al：RAVE study group：Ranibizumab in preproliferative（ischemic）central retinal vein occlusion：the rubeosis anti-VEGF（RAVE）trial. Retina 34：1728-1735, 2014